Press Releases
Archives
Public Relations Contacts
Font Size:
May 8, 2008
ABILIFY® (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia
May 8, 2008
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features
March 10, 2008
Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex
December 21, 2007
New Drug Application for Tolvaptan, Otsuka’s Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
December 17, 2007
Otsuka Pharmaceutical, Co., Ltd. Acquires Rights to IV Busulfex from PDL Biopharma, Inc.
September 19, 2007
ECLIPSE Data on Effects of Otsuka’s Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients’ Hemodynamics and Urine Output Featured in Heart Failure Society of America’s Late Breaking Trials
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989